Amarin is still in a holding pattern, waiting for an FDA ruling on its key drug Vascepa's NCE status, but that didn't stop Citigroup from initiating coverage with a buy recommendation and a $20 price target that is a near double from where shares sit today. Watch as Motley Fool health-care analyst David Williamson discusses why Citi likes Amarin so much and whether he agrees with that assessment.
